Access to services for people with multiple sclerosis (MS) is well known to be varied, with phrases like ‘postcode lottery’ and ‘patchy’ commonly used to describe people’s access to the care and support that they need.
Anecdotally known of for some time, recent evidence now highlights not just the variation, but the impact it has on the lives of people with MS – and the NHS budgets supporting them. National charities the MS Society and the MS Trust, as well as the Royal College of Physicians have all carried out research in this area lately. The problem took centre stage at the Association of British Neurologists’ annual conference this year when data was presented from NHS England’s Bluteq database, which vets and tracks the prescribing of high-cost drugs.
This variance in NHS services leads to less than optimal care for people with MS and causes frustration amongst the professionals supporting them as they come up against barriers to improving outcomes for their patients. Most well-documented, and highlighted by the Bluteq findings, is the varied access to different disease-modifying treatments. These can revolutionise someone’s lived experience of relapsing-remitting MS, and l improve their quality of life, reducing their relapses noticeably.
The Neurology Academy is hosting an initial meeting to address variance, bringing together key stakeholders from across England. Anyone linked to an MS prescribing centre is invited to join us. We want to stimulate discussion, generate ideas and come up with solutions to this problem.
Hearing from a selection of eminent individuals to inspire us, we will then collectively generate solutions to local, regional, and national variance issues. Opening the meeting, Dr Charlie Davie, CEO of UCL Partners, will question whether variation is warranted in the NHS and how it could be leveraged to justify the implementation of systems to reduce variations and improve outcomes. Further speakers such as Ben Bridgwater and Dr Geraint Fuller will give examples of existing methods of improving outcomes. Dr Waqar Rashid of the ABN MS Specialist Interest Group, will present the new NHSE DMT Treatment Algorithm and how it could be used to reduce variation. A range of other key stakeholders will also share their roles in improving outcomes for people with MS.
Our hope is that, inspired by these examples and armed with better understanding of each others’ roles, we can together come up with actionable solutions, creating lasting change in our healthcare system. We plan to host follow-on meetings to motivate implementation and map improvement, testing out the potential solutions we have developed together.
Take a look at the programme here.
Posted in: MS Variance